What is Peramivir?

Peramivir is a strong, intravenously managed new anti-viral mediator that quickly serves soaring plasma absorptions to the infected regions. The drug has been discovered, developed and produced by BioCryst and it slows down the exchanges of flu neuraminidase, a stimulant which is important to the increase or development of virus in the patient. The results and action of Peramivir has been tested in the laboratory against numerous influenza viruses including pandemic H1N1 and H7N9. It has shown good results against viral strains like swine flu. The overall cost for research and development of Peramivir has been approximated as under $234.8 million. The contract was financed by BARDA/HHS. Peramivir has been launched in Japan as RAPIACTA by Shionogi & Co. Ltd in January 2010. Moreover, Green Cross Corporation has got the marketing and manufacturing rights for intravenous Peramivir in the jurisdiction of Korea for treatment of patients suffering with avian influenza, H1N1 and other A & B viruses.

What is influenza?

The disease of influenza is commonly pronounced as “the flue”. It is an infectious disease found in mammals and birds. Patients suffering with influenza can observe some common symptoms as runny nose, chills, sore throat, fever, muscle pains, coughing, headache, fatigue/weakness and general discomfort. Sometimes, influenza produces vomiting and nausea especially in case of infants. Air is used as the career for influenza viruses by sneezes or cough. Moreover, direct contact with sufferer’s nasal secretions or bird droppings can also become a cause of influenza. In many cases, it can lead to bacterial pneumonia or viral pneumonia.

Abount BioCryst

BioCryst Pharmaceuticals devises, develops and optimizes fresh minute molecule medicines that chunk major stimulants implicated in transferable and uncommon ailments, with the objective of dealing with unmet remedial requirements of physicians and patients. Currently, the company has defined its core development programs that are concentrated towards production of BCX4161 and development of two future generation oral determents of kallikrein plasma for traditional angioedema, BCX4430 and Peramivir. The company is determined to help and serve patients suffering with enduring infectious diseases through research and development.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites